International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 2 , Pages 409-413 , 1 June 2010

Phase I Study of Daily Irinotecan as a Radiation Sensitizer for Locally Advanced Pancreatic Cancer

  • Christelle de la Fouchardière, M.D.

      Affiliations

    • Department of Medical Oncology, University of Lyon–Centre Léon Bérard, Lyon, France
    • Corresponding Author InformationReprint requests to: Christelle de la Fouchardière, M.D., Department of Medical Oncology, Centre Léon Bérard, 28 rue Laënnec 69373 Lyon Cedex 08, France. Tel: (+33) 4 78 78 27 51; Fax: (+33) 4 78 78 27 16
    • ,
  • Sylvie Négrier, M.D., Ph.D.

      Affiliations

    • Department of Medical Oncology, University of Lyon–Centre Léon Bérard, Lyon, France
    • ,
  • Hugues Labrosse, M.D.

      Affiliations

    • Department of Surgery, Infirmerie Protestante, Lyon, France
    • ,
  • Isabelle Martel Lafay, M.D.

      Affiliations

    • Department of Radiation Therapy, University of Lyon–Centre Léon Bérard, Lyon, France
    • ,
  • Françoise Desseigne, M.D.

      Affiliations

    • Department of Medical Oncology, University of Lyon–Centre Léon Bérard, Lyon, France
    • ,
  • Pierre Méeus, M.D.

      Affiliations

    • Department of Surgery, University of Lyon–Centre Léon Bérard, Lyon, France
    • ,
  • David Tavan, M.D.

      Affiliations

    • Department of Gastrointestinal Medicine, Infirmerie Protestante, Lyon, France
    • ,
  • Fabien Petit-Laurent, M.D.

      Affiliations

    • Department of Gastrointestinal Medicine, Centre Hospitalier, Villefranche-sur-Saône, France
    • ,
  • Michel Rivoire, M.D., Ph.D.

      Affiliations

    • Department of Surgery, University of Lyon–Centre Léon Bérard, Lyon, France
    • ,
  • David Pérol, M.D.

      Affiliations

    • Department of Biostatistics, University of Lyon–Centre Léon Bérard, Lyon, France
    • ,
  • Christian Carrie, M.D.

      Affiliations

    • Department of Radiation Therapy, University of Lyon–Centre Léon Bérard, Lyon, France

Received 25 February 2009 ,Revised 29 April 2009 ,Accepted 4 May 2009.

References 

  1. Yeo CJ, Yeo TP, Hruban RH. Cancer of the pancreas. In:  DeVita VTJ,  Hellman S,  Rosenberg SA editor. Cancer: Principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 2005;p. 1054–1084
  2. Wisinski KB, Wahl AO, Small W, et al. Inoperable pancreatic cancer: Standard of care. Oncology. 2007;21:1558–1564
  3. Dickler A, Abrams RA. Radiochemotherapy in the management of pancreatic cancer—Part II: Use in adjuvant and locally unresectable settings. Semin Radiat Oncol. 2005;15:235–244
  4. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705–1710
  5. Poggi MM, Kroog GS, Russo A, et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2002;54:670–676
  6. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–1599
  7. Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Cancer Res. 1989;49:605–612
  8. Mattern MR, Hofmann GA, McCabe FL, et al. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res. 1991;51:5813–5816
  9. Minsky BD, O'Reilly I, Wang D. Daily low dose irinotecan (CPT11) plus pelvis irradiation as preoperative treatment of locally advanced rectal cancer. [Abstract 1023] Proc Am Soc Clin Oncol. 1999;18:266
  10. Konstadoulakis MM, Antonakis PT, Tsibloulis BG, et al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2001;48:417–420
  11. Taieb J, Lecomte T, Aparicio T, et al. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: Results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol. 2007;18:498–503
  12. Jansman FG, Sleijfer DT, de Graaf JC, et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 2001;24:353–367
  13. ICRU Report 62. Bethesda (MD): International Commission on Radiation Units & Measurements; 1999;
  14. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  15. Iles S, Gollins S, Susnerwala S, et al. Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: A phase I/II study. Br J Cancer. 2008;98:1210–1216
  16. Grabenbauer GG, Buchfelder M, Schrell U, et al. Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma. Front Radiat Ther Oncol. 1999;33:364–368
  17. Terret C, Couteau C, Armand JP. CPT-11: The European clinical development. J Infus Chemother. 1996;6:152–157
  18. Yip D, Karapetis C, Strickland A, et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006;3:CD002093
  19. Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—An Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:373–378
  20. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–3516
  21. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751–755

 Conflict of interest: Christian Carrie, M.D., has obtained research funding from Pfizer.

PII: S0360-3016(09)00730-5

doi: 10.1016/j.ijrobp.2009.05.008

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 2 , Pages 409-413 , 1 June 2010

Article Tools